Brief: Tempest Therapeutics Terminated Prior Sales Agreement And Entered New Open Market Sale Agreement
20/06/2024 14:44
June 20 (Reuters) - Tempest Therapeutics Inc TPST.O :
* TEMPEST THERAPEUTICS: CO & AGENT TERMINATED PRIOR SALES
AGREEMENT, ENTERED NEW OPEN MARKET SALE AGREEMENT
* TEMPEST THERAPEUTICS INC: POST SALES AGREEMENT, WILL BE
ABLE TO
OFFER AND SELL UP TO $205 MILLION OF SHARES OF COMMON STOCK
Source text for Eikon: ID:n0001193125-24-164015
Further company coverage: TPST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T